作为中国医药工业体系中的"隐形巨擘"，某总部位于华东的医药集团（以下简称"该集团"或"集团"）长 期占据中国医药工业百强榜首位置，其发展历程是中国本土药企从"仿制药规模化"向"创新药差异化"转 型的经典缩影。 本报告对该集团进行了全方位的解构，核心发现包括： 1. 集团概况与历史沿革：从地方小厂到行业巨头 1.1 创始背景与早期积累（1971-2000） 该集团的历史可以追溯到1971年。创始人在江苏省泰州市的一个口岸镇创办了集团的前身。创业初期， 企业主要以生产板蓝根、维生素等基础药物为主，不仅面临资金短缺，更受限于当时计划经济体制下的 统购统销模式。 在1980年代至1990年代，创始人敏锐地抓住了中国医疗卫生体制改革的机遇，确立了"质量兴企"的战略 基石。不同于当时许多乡镇企业追求短期利益的做法，该集团在早期就建立了严格的质量内控标准，这 为其后来在"板蓝根大战"等行业洗牌中脱颖而出奠定了基础。集团充分利用长三角（上海、苏州、杭 州）的地理优势，逐步建立了覆盖华东、辐射全国的销售网络。 1.2 爆发式增长与行业霸主地位（2000-2019） 进入21世纪，该集团迎来了黄金发展期。2003年至2010年间 ...

中国除湿机行业调研简报 | 2025/10 www.leadleo.com 报告标签：除湿机、家用、锂电、医药 2025年10月 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性文件（在报告中另行标明出处者除外）。未经头豹 研究院事先书面许可，任何人不得以任何方式擅自复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究 院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹"的商号、商标，头豹研究院无任何前述名 称之外的其他分支机构，也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 1 头豹调研简报 | 2025/10 除湿机行业 Q1：当前除湿机已从单一功能设备发展为类型多样、应用场景高度多元的空 气环境调节产品，主要的产品类型及应用场景有哪些？ 图表1：除湿机基于不同工作原理与使用场景的分类 压缩冷凝式除湿机 工作原理类似于空调制冷过程，利用压缩机驱动制冷剂循环，使潮湿空气通过低温蒸发器，空气中的水汽 冷凝成液态水排出，干燥后的空气经冷凝器加热后回流到室内。具备技术成熟、价格低 ...

Core Viewpoint - Yifan Pharmaceutical's subsidiary Yiyisheng Biotechnology has received approval from the National Medical Products Administration for the clinical trial of F-652, a novel drug aimed at treating graft-versus-host disease (GVHD) [1] Group 1: Product Development - F-652 is a recombinant human interleukin 22-Fc fusion protein developed using the company's proprietary Di-KineTM dual-molecule technology platform [1] - The drug is the first of its kind (Class 1 innovative biopharmaceutical) and is designed to mimic the activity of natural interleukin 22 in the body [1] - The Fc fragment fused to the drug significantly extends its half-life, thereby enhancing clinical efficacy [1] Group 2: Clinical Trial Approval - The National Medical Products Administration has granted a Clinical Trial Approval Notice for the Phase II clinical trial of F-652 [1] - This approval marks a significant milestone in the development of F-652 for treating GVHD [1]

Group 1 - The core business of the company is traditional Chinese medicine, which has laid a solid foundation for its growth, with key products covering various medical terminals in China [2][3] - The company is expanding into the biopharmaceutical sector, with its investment in Zhejiang Teruisi Pharmaceutical Co., Ltd. entering a value realization phase, particularly with the ADC drug TRS005 receiving breakthrough therapy designation [1][5][7] - The company has launched a new innovative Chinese medicine product, Qingjiang Hewei Granules, which targets a complex condition with limited treatment options, potentially opening a market worth over 1 billion yuan [3][4] Group 2 - The biopharmaceutical market is experiencing significant growth, with ADCs being recognized as a promising platform product, projected to exceed $16.4 billion globally by 2026 [5] - The company has made strategic investments in the biopharmaceutical field, with Teruisi's TRS005 focusing on unmet clinical needs in non-Hodgkin lymphoma, marking a significant step in the company's transformation [6][7] - The company is also advancing in the chemical drug sector, with its independently developed raw material for an antihistamine drug receiving regulatory approval, indicating a strong market presence in a high-barrier segment [8][9] Group 3 - The company's dual-track strategy in chemical drugs, focusing on both raw materials and formulations, has been successfully implemented, enhancing its competitive position in the market [9][10] - The combination of traditional Chinese medicine, biopharmaceuticals, and chemical drugs creates a diversified growth strategy for the company, ensuring a more certain trajectory for future performance [10]

Core Viewpoint - Fosun Pharma (600196)(02196) announced its participation as a limited partner (LP) in a target fund with a cash investment of RMB 100 million, aimed at investing in strategic emerging sectors such as chemical innovative drugs, biopharmaceuticals (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology [1] Group 1 - The investment involves collaboration with 11 other investors under a partnership agreement signed on October 28, 2025 [1] - The target fund will focus on leveraging the strengths of both Fosun Pharma and China Resources Pharmaceutical in the health sector [1] - The investment strategy aligns with local industrial policies and geographical advantages in Chengdu, aiming to expand the company's presence in innovative drugs, biopharmaceuticals, high-end medical devices, synthetic biology, and other strategic emerging fields [1]

Core Viewpoint - The company continues to experience high growth in performance and profitability, with significant increases in revenue and net profit in the first half of 2025 [1] Financial Performance - The company achieved revenue of 390 million yuan in the first half of 2025, representing a year-on-year growth of 29.4% [1] - The net profit attributable to the parent company was 80 million yuan, showing a year-on-year increase of 47.8% [1] Domestic and International Sales - Domestic sales revenue reached 120 million yuan, growing by 36.7% year-on-year [1] - International sales revenue was 260 million yuan, with a year-on-year growth of 22.9% [1] - The rapid growth in domestic sales is attributed to the recovery of the innovative drug market and increased efforts in new product development [1] Product Development and Market Expansion - The company is actively expanding its product and technical services in the ADC field, including various target proteins and enzymes for linker cleavage [1] Profit Forecast and Investment Recommendation - The company maintains its profit forecast, predicting net profits of 154 million yuan, 208 million yuan, and 253 million yuan for 2025-2027 [1] - Based on the average price-to-earnings ratio of comparable companies, a target price of 67.34 yuan is set for 2025, with a "buy" rating maintained [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [6][12]. Core Insights - The company has successfully completed the Phase III clinical trial for its IL-17A/F monoclonal antibody, LZM012, demonstrating superior efficacy compared to the control group, Secukinumab, in treating moderate to severe plaque psoriasis [3][4]. - LZM012 achieved a PASI 100 response rate of 49.5% at week 12, compared to 40.2% for Secukinumab, indicating a significant therapeutic advantage [4]. - The company is positioned to capitalize on the growing market for biologics in psoriasis treatment, with an estimated 6-7 million patients in China and increasing penetration of targeted biologic therapies [5]. Financial Projections - The company is projected to achieve net profits of 2.372 billion, 2.683 billion, and 3.046 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 16.74, 14.79, and 13.03 [6][9]. - Revenue is expected to grow from 11.812 billion yuan in 2024 to 14.695 billion yuan in 2027, reflecting a compound annual growth rate of approximately 8.6% [9][10]. - The EBITDA is forecasted to increase from 3.373 billion yuan in 2024 to 4.429 billion yuan in 2027, indicating strong operational performance [9][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is entering a realization phase for its biopharmaceuticals, with expectations of an upward turning point [1] - The company achieved a revenue of 3.924 billion yuan in 2024, a slight decrease of 0.20% year-over-year, while the net profit attributable to shareholders increased significantly by 536.09% to 826 million yuan [1][9] - The first quarter of 2025 saw a revenue of 885 million yuan, down 11.85% year-over-year, and a net profit of 85 million yuan, down 52.19% year-over-year [1] Revenue and Profitability - The company's revenue from non-heparin formulations is expected to drive growth in overseas formulations, with a projected revenue of 3.050 billion yuan from formulations in 2024, representing a year-over-year increase of 10.05% [1][2] - The revenue from non-heparin formulations reached 1.467 billion yuan in 2024, showing a year-over-year growth of 24.25% [1][2] - The company’s heparin raw material revenue is declining, with a projected revenue of 787 million yuan in 2024, accounting for 20.06% of total revenue [2] Future Growth Drivers - The company is expected to see significant growth from its high-margin biopharmaceutical product line, which is entering a realization phase [2][3] - The company has received FDA approvals for several products, including Liraglutide in April 2025, which is anticipated to enhance its international market presence [1][2] Financial Forecasts - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.65 yuan, 0.90 yuan, and 1.22 yuan respectively [3][9] - The company’s revenue is expected to grow to 4.785 billion yuan in 2025, representing a year-over-year increase of 21.95% [9] Market Position - The company is successfully transitioning from a traditional raw material supplier to an international sterile injection enterprise, with a focus on quality and cost leadership [2]

Core Viewpoint - Northeast Pharmaceutical is committed to strategic transformation through innovation and management reform, aiming to enhance operational quality and transition from a traditional chemical drug leader to a biopharmaceutical leader [1] Group 1: Strategic Focus and Innovation - The company is focusing on strategic acquisitions, particularly the acquisition of Dingcheng Peptide Source, to commercialize innovative results in cell therapy [1][2] - Northeast Pharmaceutical has established a product matrix covering various fields, including oncology and autoimmune diseases, driven by a dual strategy of "innovative drugs + generic drugs" [2][3] - The company has developed over 10 tumor-targeted cell immunotherapy products, with DCTY1102 injection expected to be the first domestic TCR-T cell drug entering Phase I clinical trials targeting KRAS G12D [2] Group 2: Management and Efficiency - Since implementing mixed ownership reform in 2018, the company has adopted new management and incentive models, enhancing operational quality and efficiency [4] - The company has achieved a 20.5% year-on-year reduction in sales expenses and an 88% increase in R&D expenses, reflecting precise resource allocation [4] - Financial stability is indicated by a decreasing debt-to-asset ratio and a significant reduction in current liabilities, lowering short-term repayment risks [4] Group 3: Global Expansion - Northeast Pharmaceutical has a strong international presence, exporting products to over 100 countries, with a notable increase in overseas sales revenue of 9.02 billion yuan, up 26.3% year-on-year [6][7] - The company is optimizing its marketing system to enhance market share and brand influence, particularly in the competitive vitamin C and phosphomycin markets [6][7] - The global layout provides a broader platform and resources, allowing the company to diversify market risks and enhance its competitive edge in international markets [7]

Investment Rating - The report indicates a bullish outlook on the major fermentation industry in China, highlighting it as a trillion-level bio-economy with diverse application scenarios that will drive the industry's growth curve [3][4]. Core Insights - Fermentation technology is becoming a core application direction in synthetic biology due to its green production, cost advantages, and technological innovations. It utilizes microbial metabolism to achieve sustainable production, significantly reducing carbon emissions and energy consumption [3][4]. - The Chinese fermentation industry is experiencing rapid growth driven by policy support, expansion of the biopharmaceutical market, and technological breakthroughs. The biopharmaceutical market is projected to grow from 218.5 billion yuan in 2017 to 620.3 billion yuan in 2024, accounting for 32% of the pharmaceutical market [4][31]. - Future development of the Chinese fermentation industry requires overcoming technical bottlenecks and accelerating cross-sector application penetration, with a focus on transforming from a pharmaceutical-dominated market to a multi-sector collaborative approach [5][34]. Summary by Sections Industry Overview - The report provides a comprehensive analysis of the current state of the fermentation industry in China and globally, including product characteristics, technological trends, and competitive landscape [3][4]. Key Drivers - The fermentation industry in China is driven by multiple factors: - Policy support from the government, which includes the incorporation of biological manufacturing into the "14th Five-Year Plan" and the implementation of carbon tax policies [4]. - The biopharmaceutical market's rapid expansion, which directly stimulates the demand for fermentation capacity [4][31]. - Technological advancements such as AI-assisted strain design and high-throughput screening that address traditional fermentation challenges [4][5]. Challenges - The industry faces challenges such as limitations in product concentration and purity, difficulties in strain selection and cultivation, and high production costs. The current market is heavily focused on the medical field, which accounts for 80% of the applications, while emerging sectors like food and agriculture have lower technological maturity [5][34]. Market Potential - The fermentation market is expected to grow significantly, with projections indicating that the global and Chinese fermentation market sizes will exceed 160 billion yuan and 120 billion yuan respectively by 2030, with a compound annual growth rate (CAGR) of 42.5% from 2024 to 2030 [47][53]. Competitive Landscape - The fermentation market is characterized by a high concentration of leading enterprises in the midstream production and processing segment, with a focus on continuous R&D investment and capacity integration to build competitive advantages [34][38]. - Key players include both international firms with established market presence and Chinese companies that are rapidly advancing in technology and market coverage [39][41].